Estrella Immunopharma Inc
For the period ended Dec 31, 2023. Filed Feb 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2023 · Filed Feb 14, 2024
ESLA$0.75+45.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Consolidated Statements of Operations
| For the Three Months Ended | For the Three Months Ended | For the Six Months Ended | For the Six Months Ended | |
|---|---|---|---|---|
| December 31, | December 31, | December 31, | December 31, | |
| 2023 | 2022 | 2023 | 2022 | |
| Operating expenses | ||||
| Research and development | $75,459 | $2,607,928 | $558,925 | $5,213,116 |
| General and administrative | 945,165 | 148,412 | 2,332,196 | 428,668 |
| Total operating expenses | 1,020,624 | 2,756,340 | 2,891,121 | 5,641,784 |
| Loss from Operations | (1,020,624) | (2,756,340) | (2,891,121) | (5,641,784) |
| Loss before income taxes | (1,020,624) | (2,756,340) | (2,891,121) | (5,641,784) |
| Income taxes provision | - | - | - | - |
| Net loss | $(1,020,624) | $(2,756,340) | $(2,891,121) | $(5,641,784) |
| Net loss applicable to common stock per share, basic and diluted | $(0.03) | $(16.33) | $(0.16) | $(44.63) |
| Weighted average common stock outstanding, basic and diluted* | 35,201,232 | 168,758 | 18,126,944 | 126,400 |
| * | Giving retroactive effect to reverse recapitalization effected on September 29, 2023 to reflect exchange ratio of approximately 0.2407 as described in Note 3 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.